Climb Bio (CLYM) Assets (2020 - 2026)

Climb Bio has reported Assets for 7 years, with the latest figure at $152.4 million in Q1 2026.

• For the quarter ending Q1 2026, Assets fell 24.09% year-over-year to $152.4 million; the trailing twelve-month figure through Mar 2026 stood at $152.4 million (down 24.09% YoY), and the FY2025 full-year result was $167.7 million, down 22.77% from the prior year.
• Assets for Q1 2026 stood at $152.4 million, down from $167.7 million in the prior quarter.
• The five-year high for Assets was $226.0 million in Q2 2024, with the low at $109.3 million in Q1 2024.
• Historically, Assets has averaged $160.0 million across 5 years, with a median of $152.4 million in 2026.
• Annual changes were most pronounced in 2023 — Assets dropped 24.83% — and 2024, when it jumped 97.1%.
• Climb Bio's Assets stood at $135.0 million in 2022, then dropped by 18.17% to $110.5 million in 2023, then jumped by 96.6% to $217.2 million in 2024, then dropped by 22.77% to $167.7 million in 2025, then decreased by 9.16% to $152.4 million in 2026.
• The last three Assets figures came in at $152.4 million (Q1 2026), $167.7 million (Q4 2025), and $182.3 million (Q3 2025), per Business Quant data.